ArQule - Articles and news items

Phase III study of tivantinib in hepatocellular carcinoma continues

Industry news / 22 March 2016 / Victoria White

ArQule and Daiichi Sankyo today announced that the independent DMC has determined that the METIV-HCC will continue to its final analysis…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+